Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23767362 | 0.89 | S1PR1 (0.51) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL23135328 | 0.86 | DRD2 (0.49) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL24970676 | 0.86 | S1PR1 (0.46) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL19159433 | 0.85 | OPRM1 (0.52) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL20153230 | 0.84 | S1PR1 (0.49) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL22859605 | 0.84 | S1PR1 (0.49) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL24179174 | 0.84 | S1PR1 (0.51) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL23518625 | 0.84 | CYP2D6 (0.50) | S1PR1S1PR3S1PR5S1PR4CYP1A2 | |
| SCHEMBL25653951 | 0.83 | S1PR1 (0.54) | S1PR1S1PR3S1PR5GNAI3GNAO1 | |
| SCHEMBL23806516 | 0.82 | S1PR1 (0.44) | S1PR1S1PR3S1PR5GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2021163339-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | S1PR1 4379/4885S1PR3 4482/4885S1PR5 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.